You are subscribed to the Drug Topics Hospital Pharmacists' Report. Unsubscribe here.

June 4, 2013

Web Version | Digital Edition | Share with a colleague

Rivaroxaban effective for PE with lower risk of bleeding

See what new data shows about the benefits of rivaroxaban, an oral blood thinner, for treating pulmonary embolism. » More

Continuing Education

The latest FDA drug approvals: What you need to know

Of the 35 new molecular entities approved by FDA in 2011, 17 are considered groundbreaking because of their potential to make a real difference in the lives of patients.

To read and print the article with TEST QUESTIONS, click here.To proceed to the online exams and earn up to 2 CPE credits, click here to login.

Coming soon - All users will be required to provide their NABP e-Profile ID when logging into the Drug Topics' FREE CPE. This new process requires all pharmacists and pharmacy technicians to provide their NABP e-Profile ID prior to accessing the system. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

Headline Headline Headline Headline

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip consequat. » More

Today's Headlines

Risk of C. difficile in households

Are interventions necessary to lower the risk of Clostridium difficile infection among households? Read data from a new study, published in April’s Journal of Infection. » More

New guidelines on antibiotics for sinus infections

The majority (90% to 98%) of sinus infections are caused by viruses and should not be treated with antibiotics, according to new guidelines from the Infectious Diseases Society of America. » More

Rituximab for RA when anti-TNF fails

Find out what a recent study reveals about using rituximab (Rituxan, Genentech) rather than a second alternative anti-tumor necrosis factor (anti-TNF) for rheumatoid arthiritis after a first anti-TNF therapy has failed. » More

Blood-pressure drug for PTSD-related nightmares

The blood-pressure medication prazosin was found to be an effective treatment to curb nightmares related to post-traumatic stress disorder, according to a poster presentation at the 20th European Congress of Psychiatry in Prague. » More

Check these out, too

• Cohort study shows risk of pulmonary embolism rises with inactivity

• Better antibiotic stewardship needed as C. difficile-associated diarrhea surges

• Antibiotic amoxicillin no help in treating acute rhinosinusitis

• Study: Adding prednisone to treatment improves rheumatoid arthritis symptoms

You might have missed...

Headline 1

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. » More

Headline 2

Headline 3

Subscribe Now!

You must click here to continue receiving the Drug Topics Hospital Pharmacists' Report

Voices

Anticoagulation Update: Title Here

JP at Large: Title Here

View from the Zoo: Title Here

Viewpoints

Regulatory and Legal

Meetings and Events

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.